WO2006067198A3 - Targeted use of engineered enzymes - Google Patents

Targeted use of engineered enzymes Download PDF

Info

Publication number
WO2006067198A3
WO2006067198A3 PCT/EP2005/057061 EP2005057061W WO2006067198A3 WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3 EP 2005057061 W EP2005057061 W EP 2005057061W WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted use
engineered enzymes
disease
defined specificity
engineered
Prior art date
Application number
PCT/EP2005/057061
Other languages
French (fr)
Other versions
WO2006067198A2 (en
Inventor
Ulrich Haupts
Andre Koltermann
Andreas Scheidig
Ulrich Kettling
Wayne Michael Coco
Original Assignee
Direvo Biotech Ag
Voetsmeier Christian
Ulrich Haupts
Andre Koltermann
Andreas Scheidig
Ulrich Kettling
Wayne Michael Coco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direvo Biotech Ag, Voetsmeier Christian, Ulrich Haupts, Andre Koltermann, Andreas Scheidig, Ulrich Kettling, Wayne Michael Coco filed Critical Direvo Biotech Ag
Priority to EP05823713A priority Critical patent/EP1827486A2/en
Publication of WO2006067198A2 publication Critical patent/WO2006067198A2/en
Publication of WO2006067198A3 publication Critical patent/WO2006067198A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention provides method for the treatment of a disease by applying a medicament comprising a protease with a defined specificity is capable to hydrolyze specific peptide bonds within a target substrate related to such disease. The proteases with such a defined specificity can further be used for related therapeutic or diagnostic purposes.
PCT/EP2005/057061 2004-12-22 2005-12-21 Targeted use of engineered enzymes WO2006067198A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05823713A EP1827486A2 (en) 2004-12-22 2005-12-21 Targeted use of engineered enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106903 2004-12-22
EP04106903.0 2004-12-22

Publications (2)

Publication Number Publication Date
WO2006067198A2 WO2006067198A2 (en) 2006-06-29
WO2006067198A3 true WO2006067198A3 (en) 2007-01-04

Family

ID=36602119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/057061 WO2006067198A2 (en) 2004-12-22 2005-12-21 Targeted use of engineered enzymes

Country Status (2)

Country Link
EP (1) EP1827486A2 (en)
WO (1) WO2006067198A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
CA2562729C (en) 2004-04-12 2013-11-12 Sandra Waugh Ruggles Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
KR101393946B1 (en) 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 Modified proteases that inhibit complement activation
KR101778174B1 (en) 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 Protease screening methods and proteases identified thereby
TWI465247B (en) 2008-04-11 2014-12-21 Catalyst Biosciences Inc Factor vii polypeptides that are modified and uses thereof
US9012186B2 (en) 2009-04-27 2015-04-21 The Board Of Trustees Of The University Of Illinois Hemicellulose-degrading enzymes
KR101511737B1 (en) * 2012-12-31 2015-04-20 대한민국 Pharmaceutical composition for prevention and treatment of degenerative brain diseases comprising inhibitor of SUMO1 and BACE1 interaction as an active ingredient
US9982287B2 (en) * 2013-12-17 2018-05-29 Novo Nordisk A/S Enterokinase cleavable polypeptides
KR20220167337A (en) 2015-03-27 2022-12-20 이매틱스 바이오테크놀로지스 게엠베하 Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (en) * 2002-05-10 2003-11-20 Direvo Biotech Ag Process for generating sequence-specific proteases by directed evolution and use thereof
WO2004067737A2 (en) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (en) * 2002-05-10 2003-11-20 Direvo Biotech Ag Process for generating sequence-specific proteases by directed evolution and use thereof
WO2004067737A2 (en) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTAMIRANO M M ET AL: "Directed evolution of new catalytic activity using the alpha/beta-barrel scaffold", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 403, no. 6770, 10 February 2000 (2000-02-10), pages 617 - 622, XP002173865, ISSN: 0028-0836 *
COOMBS G.S.: "Directing sequence-specific proteolysis to new targets.", J BIOL. CHEM., vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4323 - 4328, XP002401171 *
HEDSTROM E ET AL: "CONVERTING TRYPSIN TO CHYMOTRYPSIN: THE ROLE OF SURFACE LOOPS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 255, no. 5049, 6 March 1992 (1992-03-06), pages 1249 - 1253, XP001179164, ISSN: 0036-8075 *
KURTH T ET AL: "Engineering the S1' subsite of trypsin: design of a protease which cleaves between dibasic residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 37, 18 August 1998 (1998-08-18), pages 11434 - 11440, XP002218040, ISSN: 0006-2960 *
SICES H J AND KRISTIE T M: "A genetic screen for the isolation of site-specific proteases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, March 1998 (1998-03-01), pages 2828 - 2833, XP002306297, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2006067198A2 (en) 2006-06-29
EP1827486A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2006067198A3 (en) Targeted use of engineered enzymes
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
WO2007081516A3 (en) Tumor activated prodrugs
MXPA05003493A (en) Methods of generating and screenign for porteases with altered specificity.
WO2005118634A3 (en) Helical peptidomimetics with enhanced activity against beta-amyloid production
EP2175834B8 (en) Glp-1-fc fusion protein formulation
WO2006052718A3 (en) Farnesyltransferase inhibitors for treating sepsis
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
WO2005097103A3 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
WO2007117482A3 (en) Renin inhibitors
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
WO2010074588A8 (en) Pharmaceutical compounds
WO2008033562A3 (en) Kinase inhibitor compounds
WO2006023629A3 (en) Treatment of pediatric multiple sclerosis
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
MX2007008065A (en) Compositions and methods for modulating gene expression using self-protected oligonucleotides.
WO2004010937A3 (en) Method of treating cancer
WO2007117557A3 (en) Diaminopropanol renin inhibitors
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007109155A3 (en) Assays for detection of antibodies to lysosomal enzymes
DE60320095D1 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES
WO2005112987A3 (en) Method of preparation and use of fibrinolytic enzymes in the treatment of disease
WO2008156701A3 (en) Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof
WO2006114105A3 (en) Use of modified factor vii for treating bleeding

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005823713

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005823713

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005823713

Country of ref document: EP